Evolution of pediatric pharmaceutical forms for treatment of Hansen's disease (leprosy).

Introduction: Leprosy is a neglected, infectious, granulomatous and chronic disease caused by the pathological agent . The course of the disease is more aggressive in patients under 15 years of age, but the current treatment offered worldwide consists of solid forms, by the combination of antibiotics such as rifampicin, clofazimine and dapsone. This represents results in lack of adherence in pediatric patients and drug therapy failure, although numerous formulations and technologies have already been developed.